“…The results showed that compared to nCABG patents, pCABG patients were associated with lower technical success (82.3% versus 87.8%; OR, 0.60; 95% CI, 0.53–0.68; P < .00001; I(2) = 0%) and procedural success (80.4% versus 86.2%; OR, 0.61; 95% CI, 0.53–0.70; P < .00001; I(2) = 10%); a higher risk of all-cause mortality (OR, 2.95; 95% CI, 1.56–5.57; P = 0.0008; I(2) = 0%), MI (OR, 2.30; 95% CI, 1.40–3.80; P = .001; I(2) = 5%), and coronary perforation (OR, 2.16; 95% CI, 1.51–3.08; P < 0.0001; I(2) = 52%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Non-enzymatically isolated primary dermal progenitor fibroblasts (FE002-SK2 cell type) served for the establishment of a clinical-grade Parental Cell Bank, based on a patented method. Optimized bioprocessing methodology for the FE002-SK2 cell type has demonstrated that extensive and consistent progenitor cell banks can be established. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This work demonstrates that Phoenix(TM) (patent pending) is a superior mechanism for transporting living cells compared to the standard method of shipping frozen cells on dry ice (−80°C) or in liquid nitrogen (−150°C), which are destructive to the biology as well as a time consuming process. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Postoperative heavily T2-weighted images were available for two subjects and showed complete obliteration of the T2-bright signal intensity in the patent SC lumen in preoperative imaging based on filling defect at the site of plugging. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Once a patent expires, generic analogue drugs are alternatives to brand name drugs. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In the complex APW group, atrial septal defect was the commonest associated cardiac lesion occurring in 8/20 (40%), followed by ventricular septal defect, interrupted aortic arch, and pulmonary artery anomalies in 25% of each. The presence of patent ductus arteriosus (PDA) was found in 40% of APW cases with 2/3rd of them in association with interrupted aortic arch. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Mortality estimates were generated for aggregate congenital heart disease and non-fatal estimates for five subcategories (single ventricle and single ventricle pathway congenital heart anomalies; severe congenital heart anomalies excluding single ventricle heart defects; critical malformations of great vessels, congenital valvular heart disease, and patent ductus arteriosus; ventricular septal defect and atrial septal defect; and other congenital heart anomalies), for 1990 through to 2017. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Fuzheng Huayu recipe (FZHY) is an original Chinese patent medicine which was developed and marketed by our institute. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Analysis focused on the top 5 patent-protected specialty and 9 traditional brand-name medications with the highest total drug expenditures by commercial insurers nationwide in 2014. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Further analysis was made on dominant issues through keyword co-occurrence, green building technologies by patent analysis, and S-curve predictions. The USA, China, and the UK are ranked the top three countries where the majority of publications come from. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…OBJECTIVE: AYUSH-64 is an Ayurvedic formulation, developed and patented by Central Council of Research in Ayurvedic Sciences, India, has been in clinical use as anti-malarial, anti-inflammatory, anti-pyretic drug for few decades. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Purpose: We investigated the use of human Cord Lining Mesenchymal Stem Cells (CL-MSCs) (US Patent number 9,737,568), in a rabbit hindlimb ischemia model, and evaluated their potential in stimulating neovascularization. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Inclusion criteria: > 65 years, +/− coronary artery bypass grafting, patent foramen ovale closure or myectomy. Exclusion criteria: bicuspid, combined valve or aortic surgery. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…IMPORTANCE: Chiral switching, a strategy in which drug manufacturers develop a single-enantiomer formulation of a drug to be substituted for a racemic formulation, allows manufacturers to maintain market exclusivity for drugs losing patent protection, even without demonstrating superior efficacy or safety. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…It has achieved many milestones, developed technologies of national eminence, organised many memorable events, successfully participated in various national missions’ time to time and published considerable amount of literature for knowledge generation in the form of research papers, patents, copyrights, books, monographs, technical peers, Calibration and Measurement Capabilities (CMCs) and study reports, etc. …”
Enlace del recurso
Enlace del recurso

“…Factors associated with acute coma were higher age, coronary artery disease, convulsions, extent of early ischemia by posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS) < 8, absence of patent posterior collateral vasculature, and occlusion over multiple segments of BA. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The odds of being at stage 1 were significantly higher for female patients (AOR, 1.35; CI, 1.29–1.42), and those with the shorter duration on ART (vs. greater than 40.37 months). Patents in rural health zones (AOR, 0.32) and semi-rural health zones (AOR, 0.79) were less likely to be at stage 1, compared to patients in urban health zones. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Out of these, left atrial appendage thrombus was found in 5, infective endocarditis in 4, atrial septal aneurysms associated with patent foramen ovale (PFO) in 3, and spontaneous mobile echo density in three patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…From Sep. 2016 and Dec. 2017, 65 patents were evaluated with a median follow-up of 24 months (range: 7–41 months). 10 patients were treatment-naïve (failure to undergo surgery or intervention due to the presence of a portal or portal branch tumor thrombus), 15 patients were treated for residual HCC after TACE as salvage therapy, and 40 cases were treated for recurrent HCC. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso